World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 13 January 2015
Main ID:  ISRCTN35391431
Date of registration: 21/11/2005
Prospective Registration: No
Primary sponsor: Imperial College London (UK)
Public title: Assessment of the palatability of elemental nutritional supplements compared to non-elemental supplements in people with pelvic cancers and people without cancer, and whether this changes following treatment with radiotherapy
Scientific title:
Date of first enrolment: 26/01/2004
Target sample size: 50
Recruitment status: Completed
URL:  http://isrctn.com/ISRCTN35391431
Study type:  Interventional
Study design:  Randomised controlled trial (Treatment)  
Phase: 
Countries of recruitment
United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name: Jervoise    Andreyev
Address:  Faculty of Medicine Imperial College Chelsea & Westminster Hospital 369 Fulham Road SW10 9NH London United Kingdom
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: Patients about to embark on a course of radical pelvic radiotherapy for pelvic malignancy
Exclusion criteria: 1. Unwilling or unable to give informed consent to participate in the study
2. A clinical condition precluding oral feeding (e.g. dysphagia, bowel obstruction)
3. Unable to tolerate milk
4. Controls with a previous history of pelvic malignancy or currently receiving chemotherapy or radiotherapy


Age minimum:
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
Pelvic (gynaecological, urological or rectal) cancers
Cancer
Pelvic
Intervention(s)
Subjects were randomised to one of five groups. Each group was assigned a target quantity of 3 different elemental sip feeds (Group 1, 20%, Group 2, 50%, Group 3, 75% of calorie requirements taken as E028 extra liquid; Group 4, 50% of calorie requirements taken as E028 extra powder; Group 5, 50% of calorie requirements taken as Emsogen powder).
Primary Outcome(s)
Taste assessed by visual analogue scale
Secondary Outcome(s)
Not provided at time of registration
Secondary ID(s)
CCR2376
Source(s) of Monetary Support
SHS International, Dr Andreyev's Personal Research Fund, Royal Marsden NHS Foundation Trust (UK)
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history